Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
复制标题
DOI：
10.1016/j.cardfail.2006.08.211
复制
发表时间：
2006-12-01
影响因子：
6
通讯作者：
Shannon, Richard P.
中科院分区：
文献类型：
--
作者：
Sokos, George G.;Nikolaidis, Lazaros A.;Shannon, Richard P.
背景：充血性心力衰竭时存在胰岛素抵抗。胰高血糖素样肽-1 (GLP-1) 是一种天然存在的肠促胰素，具有促胰岛素和拟胰岛素特性。 方法和结果：我们研究了 12 名纽约心脏协会 III/IV 级心力衰竭患者在标准治疗中添加 5 周输注 GLP-1 (2.5 pmol/ kg/min) 的安全性和有效性，并将结果与 9 名接受标准治疗的心力衰竭患者的结果进行了比较 独自的。评估了超声心动图、最大心肌通气耗氧量 (VO2\ max)、6 分钟步行测试和明尼苏达心力衰竭生活质量评分 (MNQOL)。各组之间的基线人口统计学、背景治疗和左心室功能障碍程度相似。 GLP-1 显着改善左心室射血分数（21 +/- 3% 至 27 +/- 3% P < .01）、最大摄氧量（10.8 +/- .9 ml/O-2/min/kg 至 13.9 +/-.6 ml/O-2/min/kg；P
Background: Insulin resistance is present in the setting of congestive heart failure. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and insulinomimetic properties.Methods and Results: We investigated the safety and efficacy of a 5-week infusion of GLP-1 (2.5 pmol/ kg/min) added to standard therapy in 12 patients with New York Heart Association class III/IV heart failure and compared the results with those of 9 patients with heart failure on standard therapy alone. Echocardiograms, maximum myocardial ventilation oxygen consumption (VO2\ max), 6-minute walk test, and Minnesota Living with Heart Failure quality of life score (MNQOL) were assessed. Baseline demographics, background therapy, and the degree of left ventricular dysfunction were similar between groups. GLP-1 significantly improved left ventricular ejection fraction (21 +/- 3% to 27 +/- 3% P < .01), VO2 max (10.8 +/- .9 ml/O-2/min/kg to 13.9 +/-.6 ml/O-2/min/kg; P